Welcome to the winter edition of European Oncology & Haematology! We hope you’ll enjoy this latest compilation of expert-authored, peer-reviewed articles, which focus on various aspects of supportive care, notably cost and management of chemotherapy-induced nausea and vomiting, treatment strategies for breast and bladder cancer, as well as FLT3 and Bmi 1, as means of targeting acute myeloid leukaemia and cancer stem cells, respectively. Thanks to all the authors who contributed their expertise to this edition, as well the members of our editorial board for their ongoing support and guidance.
Our Editor-in-Chief, Axel Merseburger, would like to welcome colleagues from the field to submit articles to our 2018 editions, please take a look at his call for submissions here for further information. Submissions can be made through our editorial system here.
Letter from the Editor-in-Chief
Call for Submissions 2018
Dear Colleagues, European Oncology & Haematology is now accepting submissions to the Summer and Winter 2018 editions. European Oncology & Haematology aims to publish topical articles, which are chosen for their evaluation of current practices and research that directly affect practitioners in the fields of oncology and haematology. Authors are invited to submit original research, […]
Potential Solutions for Sustaining the Costs of Cancer Drugs
Introduction With the growing burden of cancer, sustainable solutions are urgently required to ensure access to effective and safe treatments for all patients.1 Health expenditure on cancer in Europe more than doubled between 1995 and 2014, increasing from €35.7 billion to €83.2 billion;2 high-cost cancer drugs are the main drivers of this increase in many […]
What Happens when the Cost of Cancer Care Becomes Unsustainable?
The estimated incidence of cancer increased by almost one third across Europe between 1995 and 2012, and this growth is predicted to continue.1,2 Compared with other diseases and disabilities, the lost years of life and productivity resulting from cancer represent a heavy drain on the global economy, especially in low- and middle-income countries, where the […]
Can we Continue to Afford Access to Cancer Treatment?
Innovation in healthcare is highly beneficial from a patient perspective; however, the introduction of new drugs, often at high cost, is placing increasing pressure on many healthcare systems.1 As a result, these systems are facing a growing crisis of affordability, both globally and locally, which is unsustainable. Oncology is the area of greatest concern. In […]
Rolapitant in the Current Management of Chemotherapy-induced Nausea and Vomiting
The authors of the aforementioned article would like to make revisions to the labels in Figure 1 as shown below. The article has been corrected online.
Endocrine Therapeutic Strategies for Patients with Hormone Receptor-positive Advanced Breast Cancer
The majority (60–75%) of all breast cancers have oestrogen and/or progesterone receptors.1 Endocrine treatment constitutes the therapeutic backbone for patients with this cancer subtype unless there is a visceral crisis or concern/proof of endocrine resistance,2 as recommended by the third European School of Oncology (ESO)/European Society for Medical Oncology (ESMO) international consensus guidelines for Advanced […]
Systemic Chemotherapy for Urothelial Cancer – How to Select Systemic Therapy in Bladder Cancer
Urothelial cancer (UC) is a common malignancy both in men and women. More than 400,000 patients are diagnosed every year and approximately 150,000 die from this disease, worldwide.1 At the same time, 5-year survival rate has only been moderately increased during the last 30 years.2 UC may arise throughout the urinary tract (urinary bladder, ureter, […]
Targeting the FLT3 Mutation in Acute Myeloid Leukaemia
Acute myeloid leukaemia (AML) is a heterogeneous clonal disorder of haematopoietic progenitor cells resulting in uncontrolled growth and accumulation of malignant white blood cells. It is the most common myeloid leukaemia in adults, with a prevalence of 3–8 cases per 100,000 adults rising to 9–17 cases per 100,000 adults aged 65 years and older. The […]
Bmi1 – A Path to Targeting Cancer Stem Cells
Since the discovery of the Polycomb group (PcG) gene family in Drosophila as repressors of homeotic (HOX) genes, PcG proteins have been implicated in a range of processes from chromosome X inactivation to stem cell plasticity and differentiation. PcG proteins execute their function through transcriptional repression of the promoter region of a target gene. Although […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!